Krystal Biotech (FRA:4KB) Current Accrued Expense: €87.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4KB Krystal Biotech Inc FRA:4KB
55 GF Score
Price €285.50
GF Value €284.71
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Krystal Biotech Current Accrued Expense?

Krystal Biotech FRA:4KB +0.81% 55 Current Accrued Expense is €87.5 Mil as of Jun. 2026. GuruFocus rates FRA:4KB with a GF Score™ of 55/100 and a GF Value™ of €284.71 (Fairly Valued). The stock has 2 warning signs investors should review.

Krystal Biotech's Current Accrued Expense for the quarter that ended in Jun. 2026 was €87.5 Mil.

Krystal Biotech's quarterly Current Accrued Expense increased from Dec. 2025 (€71.3 Mil) to Mar. 2026 (€74.1 Mil) and increased from Mar. 2026 (€74.1 Mil) to Jun. 2026 (€87.5 Mil).

Krystal Biotech's annual Current Accrued Expense increased from Dec. 2023 (€21.4 Mil) to Dec. 2024 (€85.1 Mil) but then declined from Dec. 2024 (€85.1 Mil) to Dec. 2025 (€71.3 Mil).

Krystal Biotech Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Current Accrued Expense Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.27 21.71 21.39 85.09 71.25

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.68 63.60 71.25 74.07 87.50
FRA:4KB
55GF Score
Krystal Biotech Inc FRA:4KB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €87.5 Mil mean?
Krystal Biotech (FRA:4KB) has a Current Accrued Expense of €87.5 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Current Accrued Expense too high?
Krystal Biotech's current Current Accrued Expense is €87.5 Mil. Overall, Krystal Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Current Accrued Expense compare to NUVL and HALO?
Krystal Biotech's Current Accrued Expense of €87.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Current Accrued Expense is €87.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €284.71, compared to a current price of €285.50 — trading 0.3% above its estimated fair value. The current Current Accrued Expense is €87.5 Mil. Krystal Biotech's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Current Accrued Expense is €87.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €285.50 is trading 0.3% above its estimated GF Value™ of €284.71. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for FRA:4KB:

  • Current Accrued Expense: €87.5 Mil
  • GF Value™: €284.71 vs. price of €285.50 (0.3% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
55GF Score

Get the complete analysis for FRA:4KB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.50
Price
€284.71
GF Value